In a press release via, “Generic drugmaker Teva Pharmaceutical Industries Ltd said it could “promptly” divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV…Teva plans to work with antitrust authorities and expects that the proposed transaction with Mylan can be completed by the end of 2015.”